MannKind | MNKD - Equity Capital And Reserves


MannKind reported $-59.2M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Adma Biologics USD 390.32M 86.99M Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
MacroGenics USD 21.2M 34.39M Mar/2026
MannKind USD -59.2M 8.17M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Novavax USD -144.76M 17.01M Mar/2026
Novo Nordisk DKK 26.56B 111.98B Jun/2025
Pfizer USD 90.1B 3.63B Mar/2026
Sanofi EUR 72.81B 1.1B Mar/2026
Xencor USD 515.63M 119.95M Mar/2026